IP Library › Granted Patent US 12,297,282
Granted Patent B2
US 12,297,282 · App. 18/182,166 · Granted May 13, 2025

Nucleic acids encoding, and methods of producing, antibodies that bind human chemokine (C—C motif) receptor 8 (CCR8)

Inventors: Lara Lewis McGrath (Arlington, MA); Fabien Dépis (Brookline, MA); Changyun Hu (Belmont, MA); Leonard G. Presta (San Francisco, CA); Joshua Adam Buggé (Arlington, MA)
Assignee: Gilead Sciences, Inc.
C07K16/2866A61P35/00A61K2039/505C07K2317/24C07K2317/41C07K2317/565C07K2317/732C07K2317/734C07K2317/76C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,297,282
App. No.
18/182,166
Granted
May 13, 2025
Kind
B2
Abstract

Provided herein are various embodiments relating to antibodies and fusion proteins and uses thereof. Some of the embodiments include antibodies that bind CCR8. Some of the embodiments include fusion proteins that bind CCR8. Such antibodies and fusion proteins can be used in methods to treat, for example, cancer.

Claims (25)

1. An isolated nucleic acid encoding a heavy chain and/or a light chain of an antibody that binds human CCR8, wherein the antibody comprises:

the heavy chain comprises a heavy chain complementarity determining region 1 (HCDR1) comprising the amino acid sequence of SEQ ID NO: 84 or 100, a heavy chain complementarity determining region 2 (HCDR2) comprising the amino acid sequence of SEQ ID NO: 85, a heavy chain complementarity determining region 3 (HCDR3) comprising the amino acid sequence of SEQ ID NO: 86; and

the light chain comprises a light chain complementarity determining region 1 (LCDR1) comprising the amino acid sequence of SEQ ID NO: 87, a light chain complementarity determining region 2 (LCDR2) comprising the amino acid sequence of SEQ ID NO: 88, and a light chain complementarity determining region 3 (LCDR3) comprising the amino acid sequence of SEQ ID NO: 89.

2. The nucleic acid of claim 1 , wherein the antibody is a monoclonal antibody.

3. The nucleic acid of claim 1 , wherein the antibody is a humanized antibody.

4. The nucleic acid of claim 1 , wherein the antibody is a full-length antibody.

5. The nucleic acid of claim 1 , wherein the antibody is an IgG1 or IgG3 antibody.

6. The isolated nucleic acid of claim 1 , wherein the isolated nucleic acid encodes the heavy chain of the antibody that binds human CCR8.

7. The isolated nucleic acid of claim 1 , wherein the isolated nucleic acid encodes the light chain of the antibody that binds human CCR8.

8. The isolated nucleic acid of claim 1 , wherein the isolated nucleic acid encodes both the heavy chain and the light chain of the antibody that binds human CCR8.

9. The isolated nucleic acid of claim 1 , wherein the isolated nucleic acid encodes a heavy chain variable region (VH) comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 92, and/or a light chain variable region (VL) comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 93.

10. The isolated nucleic acid of claim 1 , wherein the isolated nucleic acid encodes a VH comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 96, and/or a VL comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 97.

11. The isolated nucleic acid of claim 1 , wherein the isolated nucleic acid encodes a VH comprising the amino acid sequence of SEQ ID NO: 92, and/or a VL comprising the amino acid sequence of SEQ ID NO: 93.

12. The isolated nucleic acid of claim 1 , wherein the isolated nucleic acid encodes a VH comprising the amino acid sequence of SEQ ID NO: 96, and/or a VL comprising the amino acid sequence of SEQ ID NO: 97.

13. The isolated nucleic acid of claim 1 , wherein the isolated nucleic acid encodes a heavy chain comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 94, and/or a light chain comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 95.

14. The isolated nucleic acid of claim 1 , wherein the isolated nucleic acid encodes a heavy chain comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 98, and/or a light chain comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 99.

15. The isolated nucleic acid of claim 1 , wherein the isolated nucleic acid encodes a heavy chain comprising the amino acid sequence of SEQ ID NO: 94, and/or a light chain comprising the amino acid sequence of SEQ ID NO: 95.

16. The isolated nucleic acid of claim 1 , wherein the isolated nucleic acid encodes a heavy chain comprising the amino acid sequence of SEQ ID NO: 98, and/or a light chain comprising the amino acid sequence of SEQ ID NO: 99.

17. A vector comprising the isolated nucleic acid of claim 1 .

18. An isolated host cell comprising the isolated nucleic acid of claim 1 .

19. The isolated host cell of claim 18 , which is engineered to produce afucosylated antibodies.

20. An isolated host cell comprising the vector of claim 17 .

21. The isolated host cell of claim 20 , which is engineered to produce afucosylated antibodies.

22. A method of producing an antibody that binds CCR8 comprising culturing the host cell of claim 18 under conditions suitable for expressing the antibody.

23. The method of claim 22 , further comprising isolating the antibody.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 28, 2023
From: JOUNCE THERAPEUTICS, INC.
To: GILEAD SCIENCES, INC.
Reel/Frame 063483/0705 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 28, 2023
From: MCGRATH, LARA LEWIS; DÉPIS, FABIEN; HU, CHANGYUN; PRESTA, LEONARD G.; BUGGÉ, JOSHUA ADAM
To: JOUNCE THERAPEUTICS, INC.
Reel/Frame 063483/0623 →
Continuity (4)
Division 17171866 · Feb 9, 2021
Provisional Application 63130157 · Dec 23, 2020
Provisional Application 62976869 · Feb 14, 2020
Related Publication 20230312736A1 · Oct 5, 2023
References Cited (400)
US 4816567A · Genentech · 1989 [cited by applicant]
US 4943593A · Palfreyman et al. · 1990 [cited by applicant]
US 4965288A · Palfreyman et al. · 1990 [cited by applicant]
US 4997854A · Kagan et al. · 1991 [cited by applicant]
US 5021456A · Palfreyman et al. · 1991 [cited by applicant]
US 5059714A · Palfreyman et al. · 1991 [cited by applicant]
US 5120764A · McCarthy et al. · 1992 [cited by applicant]
US 5182297A · Palfreyman et al. · 1993 [cited by applicant]
US 5252608A · Palfreyman et al. · 1993 [cited by applicant]
US 5500362A · Robinson et al. · 1996 [cited by applicant]
US 5750373A · Garrard et al. · 1998 [cited by applicant]
US 5770429A · Lonberg et al. · 1998 [cited by applicant]
US 5821337A · Carter et al. · 1998 [cited by applicant]
US 6075181A · Kucherlapati et al. · 2000 [cited by applicant]
US 6150584A · Kucherlapati et al. · 2000 [cited by applicant]
US 6194551B1 · Idusogie et al. · 2001 [cited by applicant]
US 6319494B1 · Capon et al. · 2001 [cited by applicant]
US 6602684B1 · Umaña et al. · 2003 [cited by applicant]
US 6737056B1 · Presta · 2004 [cited by applicant]
US 6982321B2 · Winter · 2006 [cited by applicant]
US 7041870B2 · Tomizuka et al. · 2006 [cited by applicant]
US 7087409B2 · Barbas · 2006 [cited by applicant]
US 7189826B2 · Rodman · 2007 [cited by applicant]
US 7527791B2 · Adams et al. · 2009 [cited by applicant]
US 7741465B1 · Eshhar et al. · 2010 [cited by applicant]
US 7923538B2 · Shitara et al. · 2011 [cited by applicant]
US 7994290B2 · Shitara et al. · 2011 [cited by applicant]
US 8450321B2 · Mitchell et al. · 2013 [cited by applicant]
US 9089520B2 · Brenner · 2015 [cited by applicant]
US 10087259B1 · Rudensky et al. · 2018 [cited by applicant]
US 10550191B2 · Yoshida et al. · 2020 [cited by applicant]
US 11639393B2 · McCluskey et al. · 2023 [cited by applicant]
US 20020164328A1 · Shinkawa et al. · 2002 [cited by applicant]
US 20030115614A1 · Kanda et al. · 2003 [cited by applicant]
US 20030157108A1 · Presta · 2003 [cited by applicant]
US 20040093621A1 · Shitara et al. · 2004 [cited by applicant]
US 20040109865A1 · Niwa et al. · 2004 [cited by applicant]
US 20040110282A1 · Kanda et al. · 2004 [cited by applicant]
US 20040110704A1 · Yamane et al. · 2004 [cited by applicant]
US 20040132140A1 · Satoh et al. · 2004 [cited by applicant]
US 20040248871A1 · Farjanel et al. · 2004 [cited by applicant]
US 20050079574A1 · Bond · 2005 [cited by applicant]
US 20050119455A1 · Fuh et al. · 2005 [cited by applicant]
US 20050123546A1 · Umana et al. · 2005 [cited by applicant]
US 20050266000A1 · Bond et al. · 2005 [cited by applicant]
US 20060270045A1 · Cregg et al. · 2006 [cited by applicant]
US 20070061900A1 · Murphy · 2007 [cited by applicant]
US 20070117126A1 · Sidhu et al. · 2007 [cited by applicant]
US 20070160598A1 · Dennis et al. · 2007 [cited by applicant]
US 20070237764A1 · Birtalan et al. · 2007 [cited by applicant]
US 20070292936A1 · Barthelemy et al. · 2007 [cited by applicant]
US 20080234251A1 · Doherty et al. · 2008 [cited by applicant]
US 20080306050A1 · Doherty et al. · 2008 [cited by applicant]
US 20090002360A1 · Chen et al. · 2009 [cited by applicant]
US 20090047249A1 · Graupe et al. · 2009 [cited by applicant]
US 20090142345A1 · Satou et al. · 2009 [cited by applicant]
US 20090214533A1 · Clynes · 2009 [cited by applicant]
US 20100029585A1 · Howbert et al. · 2010 [cited by applicant]
US 20100143301A1 · Desai et al. · 2010 [cited by applicant]
US 20110092485A1 · Howbert et al. · 2011 [cited by applicant]
US 20110098248A1 · Halcomb et al. · 2011 [cited by applicant]
US 20110118235A1 · Howbert et al. · 2011 [cited by applicant]
US 20110287011A1 · Gurney et al. · 2011 [cited by applicant]
US 20120082658A1 · Hershberg · 2012 [cited by applicant]
US 20120219615A1 · Hershberg et al. · 2012 [cited by applicant]
US 20130251673A1 · Hartman et al. · 2013 [cited by applicant]
US 20140045849A1 · McGowan et al. · 2014 [cited by applicant]
US 20140066432A1 · Howbert et al. · 2014 [cited by applicant]
US 20140073642A1 · McGowan et al. · 2014 [cited by applicant]
US 20140088085A1 · Burgess et al. · 2014 [cited by applicant]
US 20140275167A1 · Hartman · 2014 [cited by applicant]
US 20140341937A1 · Biragyn et al. · 2014 [cited by applicant]
US 20140350031A1 · McGowan et al. · 2014 [cited by applicant]
US 20150175616A1 · Blomgren et al. · 2015 [cited by applicant]
US 20150352206A1 · Gajewski et al. · 2015 [cited by applicant]
US 20160060237A1 · Balog et al. · 2016 [cited by applicant]
US 20160303196A1 · Karin et al. · 2016 [cited by applicant]
US 20170088627A1 · Lin et al. · 2017 [cited by applicant]
US 20210277129A1 · McGrath et al. · 2021 [cited by applicant]
CN 109476755A · 2019 [cited by applicant]
CN 110392694A · 2019 [cited by applicant]
CN 110835371A · 2020 [cited by applicant]
EP 3431105A1 · 2019 [cited by applicant]
EP 3616720B1 · 2021 [cited by applicant]
WO WO1987004462A1 · 1987 [cited by applicant]
WO WO1992003459A1 · 1992 [cited by applicant]
WO WO1992021766A1 · 1992 [cited by applicant]
WO WO1997027873A1 · 1997 [cited by applicant]
WO WO1997030087A1 · 1997 [cited by applicant]
WO WO1998058964A1 · 1998 [cited by applicant]
WO WO1999010494A2 · 1999 [cited by applicant]
WO WO1999022764A1 · 1999 [cited by applicant]
WO WO1999025734A2 · 1999 [cited by applicant]
WO WO1999040940A1 · 1999 [cited by applicant]
WO WO1999051642A1 · 1999 [cited by applicant]
WO WO2000061739A1 · 2000 [cited by applicant]
WO WO2001029246A1 · 2001 [cited by applicant]
WO WO2001040307A1 · 2001 [cited by applicant]
WO WO2002031140A1 · 2002 [cited by applicant]
WO WO2002092784A2 · 2002 [cited by applicant]
WO WO2003011878A2 · 2003 [cited by applicant]
WO WO2003084570A1 · 2003 [cited by applicant]
WO WO2003085107A1 · 2003 [cited by applicant]
WO WO2003085119A1 · 2003 [cited by applicant]
WO WO2004056312A2 · 2004 [cited by applicant]
WO WO2004080462A1 · 2004 [cited by applicant]
WO WO2004092219A2 · 2004 [cited by applicant]
WO WO2005020921A2 · 2005 [cited by applicant]
WO WO2005035586A1 · 2005 [cited by applicant]
WO WO2005035778A1 · 2005 [cited by applicant]
WO WO2005044857A1 · 2005 [cited by applicant]
WO WO2005053742A1 · 2005 [cited by applicant]
WO WO2005113556A1 · 2005 [cited by applicant]
WO WO2005113595A2 · 2005 [cited by applicant]
WO WO2006009755A2 · 2006 [cited by applicant]
WO WO2006031221A1 · 2006 [cited by applicant]
WO WO2006063466A1 · 2006 [cited by applicant]
WO WO2006081430A2 · 2006 [cited by applicant]
WO WO2006124692A2 · 2006 [cited by applicant]
WO WO2006124944A1 · 2006 [cited by applicant]
WO WO2007032255A1 · 2007 [cited by applicant]
WO WO2007044756A2 · 2007 [cited by applicant]
WO WO2007059610A1 · 2007 [cited by applicant]
WO WO2007078034A1 · 2007 [cited by applicant]
WO WO2007092403A1 · 2007 [cited by applicant]
WO WO2007124589A1 · 2007 [cited by applicant]
WO WO2007127317A2 · 2007 [cited by applicant]
WO WO2007133811A2 · 2007 [cited by applicant]
WO WO2007137767A1 · 2007 [cited by applicant]
WO WO2007139791A2 · 2007 [cited by applicant]
WO WO2008005877A2 · 2008 [cited by applicant]
WO WO2008071173A1 · 2008 [cited by applicant]
WO WO2008077546A1 · 2008 [cited by applicant]
WO WO2009017833A2 · 2009 [cited by applicant]
WO WO2009035791A1 · 2009 [cited by applicant]
WO WO2009046541A1 · 2009 [cited by applicant]
WO WO2009064250A1 · 2009 [cited by applicant]
WO WO2009064251A1 · 2009 [cited by applicant]
WO WO2009082347A1 · 2009 [cited by applicant]
WO WO2009103778A1 · 2009 [cited by applicant]
WO WO2009117985A1 · 2009 [cited by applicant]
WO WO2009117987A2 · 2009 [cited by applicant]
WO WO2009130242A1 · 2009 [cited by applicant]
WO WO2009138376A1 · 2009 [cited by applicant]
WO WO2009146696A1 · 2009 [cited by applicant]
WO WO2010034796A1 · 2010 [cited by applicant]
WO WO2010034797A1 · 2010 [cited by applicant]
WO WO2010034798A1 · 2010 [cited by applicant]
WO WO2010034799A1 · 2010 [cited by applicant]
WO WO2010070047A1 · 2010 [cited by applicant]
WO WO2010083253A2 · 2010 [cited by applicant]
WO WO2010100249A1 · 2010 [cited by applicant]
WO WO2010106431A2 · 2010 [cited by applicant]
WO WO2011008709A1 · 2011 [cited by applicant]
WO WO2011023812A1 · 2011 [cited by applicant]
WO WO2011048004A1 · 2011 [cited by applicant]
WO WO2011062634A2 · 2011 [cited by applicant]
WO WO2011076781A1 · 2011 [cited by applicant]
WO WO2011097513A1 · 2011 [cited by applicant]
WO WO2011143624A2 · 2011 [cited by applicant]
WO WO2012022792A1 · 2012 [cited by applicant]
WO WO2012022793A1 · 2012 [cited by applicant]
WO WO2012027721A2 · 2012 [cited by applicant]
WO WO2012054825A1 · 2012 [cited by applicant]
WO WO2012076672A1 · 2012 [cited by applicant]
WO WO2012076673A1 · 2012 [cited by applicant]
WO WO2012079000A1 · 2012 [cited by applicant]
WO WO2012082647A2 · 2012 [cited by applicant]
WO WO2012087771A1 · 2012 [cited by applicant]
WO WO2012110860A1 · 2012 [cited by applicant]
WO WO2012154480A1 · 2012 [cited by applicant]
WO WO2012161965A1 · 2012 [cited by applicant]
WO WO2012170250A1 · 2012 [cited by applicant]
WO WO2012172341A2 · 2012 [cited by applicant]
WO WO2013024898A1 · 2013 [cited by applicant]
WO WO2013027802A1 · 2013 [cited by applicant]
WO WO2013034933A1 · 2013 [cited by applicant]
WO WO2013039889A1 · 2013 [cited by applicant]
WO WO2013041865A1 · 2013 [cited by applicant]
WO WO2013052699A2 · 2013 [cited by applicant]
WO WO2013056352A1 · 2013 [cited by applicant]
WO WO2013072825A1 · 2013 [cited by applicant]
WO WO2013109752A1 · 2013 [cited by applicant]
WO WO2013112741A1 · 2013 [cited by applicant]
WO WO2013116562A1 · 2013 [cited by applicant]
WO WO2013118071A1 · 2013 [cited by applicant]
WO WO2013119714A1 · 2013 [cited by applicant]
WO WO2013131010A2 · 2013 [cited by applicant]
WO WO2013153535A1 · 2013 [cited by applicant]
WO WO2013186692A1 · 2013 [cited by applicant]
WO WO2014023813A1 · 2014 [cited by applicant]
WO WO2014039714A2 · 2014 [cited by applicant]
WO WO2014047624A1 · 2014 [cited by applicant]
WO WO2014056953A1 · 2014 [cited by applicant]
WO WO2014064215A1 · 2014 [cited by applicant]
WO WO2014076221A1 · 2014 [cited by applicant]
WO WO2014087248A2 · 2014 [cited by applicant]
WO WO2014100620A2 · 2014 [cited by applicant]
WO WO2014100765A1 · 2014 [cited by applicant]
WO WO2014100767A1 · 2014 [cited by applicant]
WO WO2014107171A1 · 2014 [cited by applicant]
WO WO2014118236A2 · 2014 [cited by applicant]
WO WO2014128189A1 · 2014 [cited by applicant]
WO WO2014167444A1 · 2014 [cited by applicant]
WO WO2014201409A1 · 2014 [cited by applicant]
WO WO2015011450A1 · 2015 [cited by applicant]
WO WO2015059618A1 · 2015 [cited by applicant]
WO WO2015134536A1 · 2015 [cited by applicant]
WO WO2015138600A2 · 2015 [cited by applicant]
WO WO2015148954A1 · 2015 [cited by applicant]
WO WO2015157386A1 · 2015 [cited by applicant]
WO WO2015158204A1 · 2015 [cited by applicant]
WO WO2015191861A1 · 2015 [cited by applicant]
WO WO2016022971A1 · 2016 [cited by applicant]
WO WO2016023040A1 · 2016 [cited by applicant]
WO WO2016024021A1 · 2016 [cited by applicant]
WO WO2016033486A1 · 2016 [cited by applicant]
WO WO2016033570A1 · 2016 [cited by applicant]
WO WO2016055785A1 · 2016 [cited by applicant]
WO WO2016069374A1 · 2016 [cited by applicant]
WO WO2016069376A1 · 2016 [cited by applicant]
WO WO2016081423A1 · 2016 [cited by applicant]
WO WO2016090300A1 · 2016 [cited by applicant]
WO WO2016100236A2 · 2016 [cited by applicant]
WO WO2016109415A1 · 2016 [cited by applicant]
WO WO2016141328A2 · 2016 [cited by applicant]
WO WO2016142783A2 · 2016 [cited by applicant]
WO WO2016149562A2 · 2016 [cited by applicant]
WO WO2016177339A1 · 2016 [cited by applicant]
WO WO2016179399A1 · 2016 [cited by applicant]
WO WO2016179517A1 · 2016 [cited by applicant]
WO WO2016188449A1 · 2016 [cited by applicant]
WO WO2016191246A2 · 2016 [cited by applicant]
WO WO2016196388A1 · 2016 [cited by applicant]
WO WO2016205042A1 · 2016 [cited by applicant]
WO WO2016205942A1 · 2016 [cited by applicant]
WO WO2016210365A2 · 2016 [cited by applicant]
WO WO2017027422A1 · 2017 [cited by applicant]
WO WO2017044661A1 · 2017 [cited by applicant]
WO WO2017049166A1 · 2017 [cited by applicant]
WO WO2017049251A2 · 2017 [cited by applicant]
WO WO2017053423A1 · 2017 [cited by applicant]
WO WO2017076308A1 · 2017 [cited by applicant]
WO WO2017096179A1 · 2017 [cited by applicant]
WO WO2017096182A1 · 2017 [cited by applicant]
WO WO2017096189A1 · 2017 [cited by applicant]
WO WO2017096276A1 · 2017 [cited by applicant]
WO WO2017096281A1 · 2017 [cited by applicant]
WO WO2017109496A1 · 2017 [cited by applicant]
WO WO2017121771A1 · 2017 [cited by applicant]
WO WO2017147410A1 · 2017 [cited by applicant]
WO WO2018172984A1 · 2017 [cited by applicant]
WO WO2017160861A1 · 2017 [cited by applicant]
WO WO2017167182A1 · 2017 [cited by applicant]
WO WO2017174822A1 · 2017 [cited by applicant]
WO WO2017174823A1 · 2017 [cited by applicant]
WO WO2017174824A1 · 2017 [cited by applicant]
WO WO2017175006A1 · 2017 [cited by applicant]
WO WO2017178653A2 · 2017 [cited by applicant]
WO WO2017189254A1 · 2017 [cited by applicant]
WO WO2017194634A1 · 2017 [cited by applicant]
WO WO2017196793A1 · 2017 [cited by applicant]
WO WO2017211303A1 · 2017 [cited by applicant]
WO WO2017215585A1 · 2017 [cited by applicant]
WO WO2018005435A1 · 2018 [cited by applicant]
WO WO2018026600A1 · 2018 [cited by applicant]
WO WO2018049152A1 · 2018 [cited by applicant]
WO WO2018049191A1 · 2018 [cited by applicant]
WO WO2018049200A1 · 2018 [cited by applicant]
WO WO2018049214A1 · 2018 [cited by applicant]
WO WO2018057669A1 · 2018 [cited by applicant]
WO WO2018075857A1 · 2018 [cited by applicant]
WO WO2018075960A1 · 2018 [cited by applicant]
WO WO2018089508A2 · 2018 [cited by applicant]
WO WO2018089628A1 · 2018 [cited by applicant]
WO WO2018095428A1 · 2018 [cited by applicant]
WO WO2018097951A1 · 2018 [cited by applicant]
WO WO2018098280A1 · 2018 [cited by applicant]
WO WO2018102366A1 · 2018 [cited by applicant]
WO WO2018107058A1 · 2018 [cited by applicant]
WO WO2018112032A1 · 2018 [cited by applicant]
WO WO2018112136A1 · 2018 [cited by applicant]
WO WO2018112140A1 · 2018 [cited by applicant]
WO WO2018119448A1 · 2018 [cited by applicant]
WO WO2018132739A2 · 2018 [cited by applicant]
WO WO2018137705A1 · 2018 [cited by applicant]
WO WO2018144649A1 · 2018 [cited by applicant]
WO WO2018170338A2 · 2018 [cited by applicant]
WO WO2018172533A2 · 2018 [cited by applicant]
WO WO2018167147A1 · 2018 [cited by applicant]
WO WO2018181425A1 · 2018 [cited by applicant]
WO WO2018183418A1 · 2018 [cited by applicant]
WO WO2018183956A1 · 2018 [cited by applicant]
WO WO2018183964A1 · 2018 [cited by applicant]
WO WO2018190719A2 · 2018 [cited by applicant]
WO WO2018195321A1 · 2018 [cited by applicant]
WO WO2018210793A2 · 2018 [cited by applicant]
WO WO2018223909A1 · 2018 [cited by applicant]
WO WO2018225732A1 · 2018 [cited by applicant]
WO WO2018226542A1 · 2018 [cited by applicant]
WO WO2018233575A1 · 2018 [cited by applicant]
WO WO2018234319A1 · 2018 [cited by applicant]
WO WO2018237026A1 · 2018 [cited by applicant]
WO WO2019023347A1 · 2019 [cited by applicant]
WO WO2019027903A1 · 2019 [cited by applicant]
WO WO2019034895A1 · 2019 [cited by applicant]
WO WO2019042119A1 · 2019 [cited by applicant]
WO WO2019042285A1 · 2019 [cited by applicant]
WO WO2019042470A1 · 2019 [cited by applicant]
WO WO2019043208A1 · 2019 [cited by applicant]
WO WO2019043217A1 · 2019 [cited by applicant]
WO WO2019067733A1 · 2019 [cited by applicant]
WO WO2019079701A1 · 2019 [cited by applicant]
WO WO2019084026A1 · 2019 [cited by applicant]
WO WO2019084030A1 · 2019 [cited by applicant]
WO WO2019084538A1 · 2019 [cited by applicant]
WO WO2019086573A1 · 2019 [cited by applicant]
WO WO2019099926A1 · 2019 [cited by applicant]
WO WO2019103203A1 · 2019 [cited by applicant]
WO WO2019108733A2 · 2019 [cited by applicant]
WO WO2019109821A1 · 2019 [cited by applicant]
WO WO2019138367A1 · 2019 [cited by applicant]
WO WO2019144895A1 · 2019 [cited by applicant]
WO WO2019155067A1 · 2019 [cited by applicant]
WO WO2019157098A1 · 2019 [cited by applicant]
WO WO2019157843A1 · 2019 [cited by applicant]
WO WO2019160882A1 · 2019 [cited by applicant]
WO WO2019162043A1 · 2019 [cited by applicant]
WO WO2019173692A2 · 2019 [cited by applicant]
WO WO2019175218A1 · 2019 [cited by applicant]
WO WO2019179366A1 · 2019 [cited by applicant]
WO WO2019183266A1 · 2019 [cited by applicant]
WO WO2019184912A1 · 2019 [cited by applicant]
WO WO2019185717A1 · 2019 [cited by applicant]
WO WO2019201236A1 · 2019 [cited by applicant]
WO WO2019204683A1 · 2019 [cited by applicant]
WO WO2019238012A1 · 2019 [cited by applicant]
WO WO2019241732A1 · 2019 [cited by applicant]
WO WO2020009725A1 · 2020 [cited by applicant]
WO WO2020013170A1 · 2020 [cited by applicant]
WO WO2020014643A1 · 2020 [cited by applicant]
WO WO2020019135A1 · 2020 [cited by applicant]
WO WO2020036977A1 · 2020 [cited by applicant]
WO WO2020043188A1 · 2020 [cited by applicant]
WO WO2020063488A1 · 2020 [cited by applicant]
WO WO2020068752A1 · 2020 [cited by applicant]
WO WO2020076105A1 · 2020 [cited by applicant]
WO WO2020086158A2 · 2020 [cited by applicant]
WO WO2020086647A1 · 2020 [cited by applicant]
WO WO2020092528A1 · 2020 [cited by applicant]
WO WO2020092621A1 · 2020 [cited by applicant]
WO WO2020112687A2 · 2020 [cited by applicant]
WO WO2020138489A1 · 2020 [cited by applicant]
WO WO2020263830A1 · 2020 [cited by applicant]
WO WO2021152186A2 · 2021 [cited by applicant]
WO WO2021163064A2 · 2021 [cited by applicant]
WO WO2021178749A2 · 2021 [cited by applicant]
WO WO2021194942A1 · 2021 [cited by applicant]
WO WO2021260210A2 · 2021 [cited by applicant]
WO WO2022000443A1 · 2022 [cited by applicant]
WO WO2022003156A1 · 2022 [cited by applicant]
WO WO2022004760A1 · 2022 [cited by applicant]
WO WO2022042690A1 · 2022 [cited by applicant]
WO WO2022078277A1 · 2022 [cited by applicant]
WO WO2022081718A1 · 2022 [cited by applicant]
WO WO2022117569A1 · 2022 [cited by applicant]
WO WO2022136647A1 · 2022 [cited by applicant]
WO WO2022136649A1 · 2022 [cited by applicant]
WO WO2022136650A1 · 2022 [cited by applicant]
WO WO2022200303A1 · 2022 [cited by applicant]
WO WO2022216965A1 · 2022 [cited by applicant]
WO WO2022241034A1 · 2022 [cited by applicant]
WO WO2023288241A1 · 2023 [cited by applicant]
WO WO2023010054A1 · 2023 [cited by applicant]
WO WO2023020621A1 · 2023 [cited by applicant]
Abdiche et al., “Determining kinetics and affinities of protein interactions using a parallel real-time label-free biosensor, the Octet,” [cited by applicant]
Almagro et al., “Humanization of antibodies,” [cited by applicant]
Baca et al., “Antibody humanization using monovalent phage display,” [cited by applicant]
Bagger et al., “BloodSpot: a database of gene expression profiles and transcriptional programs for healthy and malignant hematopoiesis,” [cited by applicant]
Bendig, “Humanization of rodent monoclonal antibodies by CDR grafting,” [cited by applicant]
BioLegend Datasheet, “Purified anti-mouse CD198 (CCR8) Antibody,” pp. 1-2 (2015). [cited by applicant]
Boerner et al., “Production of antigen-specific human monoclonal antibodies from in vitro-primed human splenocytes,” [cited by applicant]
Booth et al., “The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5-dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib,” [cited by applicant]
Brodeur et al., “Mouse-Human Myeloma Partners for the Production of Heterohybridomas,” [cited by applicant]
Capel et al., “Heterogeneity of human IgG Fc receptors,” [cited by applicant]
Carreno et al., “Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells,” [cited by applicant]
Carter et al., “Humanization of an anti-p185HER2 antibody for human cancer therapy,” [cited by applicant]
Casset et al., “A peptide mimetic of an anti-CD4 monoclonal antibody by rational design,” [cited by applicant]
Chen et al., “Enhancement and destruction of antibody function by somatic mutation: unequal occurrence is controlled by V gene combinatorial associations,” [cited by applicant]
Chen et al., “Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen,” [cited by applicant]
Chiossone et al., “Natural killer cells and other innate lymphoid cells in cancer,” [cited by applicant]
Choo et al., “SPdb—a signal peptide database,” [cited by applicant]
Chothia et al., “Canonical structures for the hypervariable regions of immunoglobulins,” [cited by applicant]
Clackson et al., “Making antibody fragments using phage display libraries,” [cited by applicant]
Clynes et al., “Fc receptors are required in passive and active immunity to melanoma,” [cited by applicant]
Collado-Torres et al., “Reproducible RNA-seq analysis using recount2,” [cited by applicant]
Daeron, “Fc receptor biology,” [cited by applicant]
Dai et al., “Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy,” [cited by applicant]
Dall'Acqua et al., “Antibody humanization by framework shuffling,” [cited by applicant]
Davis et al., “Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy,” [cited by applicant]
Cited By (1)
US 12,729,241